Wealth Effects LLC Has $396,000 Stock Holdings in TG Therapeutics, Inc. $TGTX

Wealth Effects LLC reduced its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 4.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 11,000 shares of the biopharmaceutical company’s stock after selling 500 shares during the period. Wealth Effects LLC’s holdings in TG Therapeutics were worth $396,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of TG Therapeutics by 1,809.9% in the first quarter. Wellington Management Group LLP now owns 1,213,039 shares of the biopharmaceutical company’s stock valued at $47,830,000 after buying an additional 1,149,526 shares during the last quarter. Driehaus Capital Management LLC acquired a new stake in TG Therapeutics during the 1st quarter valued at $30,545,000. Nuveen LLC bought a new position in TG Therapeutics during the first quarter worth $29,442,000. Woodline Partners LP acquired a new position in shares of TG Therapeutics in the first quarter valued at $21,021,000. Finally, Goldman Sachs Group Inc. raised its position in shares of TG Therapeutics by 21.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Price Performance

TGTX stock opened at $35.57 on Wednesday. The company’s 50-day moving average price is $31.79 and its two-hundred day moving average price is $35.63. The firm has a market cap of $5.64 billion, a P/E ratio of 96.14 and a beta of 1.88. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 12 month low of $21.16 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The business had revenue of $141.15 million during the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business’s quarterly revenue was up 92.1% compared to the same quarter last year. During the same period last year, the business earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Insider Buying and Selling at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the sale, the director directly owned 94,061 shares in the company, valued at $3,032,526.64. This represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.64% of the company’s stock.

Analyst Ratings Changes

TGTX has been the topic of a number of research reports. B. Riley upped their price target on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 price target for the company in a report on Thursday, July 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $48.00.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.